# OnCo record peripheral-t-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/peripheral-t-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "peripheral-t-cell-lymphoma" ;
  schema:name "Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)"@en ;
  schema:alternateName "PTCL"@en, "CTCL"@en, "Mycosis fungoides"@en, "Anaplastic large-cell lymphoma"@en ;
  schema:description "Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."@en ;
  schema:url <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Peripheral_T-cell_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7168693> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483>, <https://doi.org/10.1016/S0140-6736(18)32984-2>, <https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/ccr4/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/pralatrexate/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/belinostat/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/haihe-biopharma/>, <https://onco.cc/companies/immuneoncia-therapeutics/> ;
  onco:terms <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/histologic-transformation/> ;
  onco:trials <https://onco.cc/trials/nct06561048/>, <https://onco.cc/trials/nct06776952/>, <https://onco.cc/trials/nct06072131/>, <https://onco.cc/trials/nct04668690/>, <https://onco.cc/trials/alcanza/>, <https://onco.cc/trials/echelon-2/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-horwitz-lancet/> ;
  onco:pipeline <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/soquelitinib/>, <https://onco.cc/drugs/azd3470/>, <https://onco.cc/drugs/dr-01/> ;
  onco:standardOfCare <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/pralatrexate/>, <https://onco.cc/drugs/belinostat/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/imrt-igrt/> .